In compliance with Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time, Phaarmasia has informed that the Company has intimated to all its Directors, Key Management Personnel and Designated Employees regarding the Closure of the Trading ‘Window of the Company from 01.04.2024 till 48 hours from the conclusion of Board meeting in which the audited financial result for the Quarter and financial year ended 31st March, 2024 will be approved. This closure of the Trading Window is occasioned by reason of declaration of financial results for the quarter and financial year ended 31st March, 2024. All the insiders (including Directors, Key Managerial Personnel and designated employees) and their immediate relatives are directed to take notice that in terms of trading restrictions placed under above regulations, shares of the Company shall not be dealt in during the period of closure of Trading Window as stated above.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1678.60 |
| Dr. Reddys Lab | 1223.40 |
| Cipla | 1232.00 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2304.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: